Eagle Asset Management’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | $85.9M | Buy |
|
|||||
|
2024
Q2 | $59.9M | Sell |
|
|||||
|
2024
Q1 | $39.6M | Sell |
|
|||||
|
2023
Q4 | $50.3M | Buy |
|
|||||
|
2023
Q3 | $46.5M | Buy |
|
|||||
|
2023
Q2 | $49.2M | Sell |
|
|||||
|
2023
Q1 | $52.8M | Sell |
|
|||||
|
2022
Q4 | $61.6M | Buy |
|
|||||
|
2022
Q3 | $52.7M | Buy |
|
|||||
|
2022
Q2 | $38.1M | Buy |
|
|||||
|
2022
Q1 | $41.8M | Buy |
|
|||||
|
2021
Q4 | $43.7M | Buy |
|
|||||
|
2021
Q3 | $47.9M | Sell |
|
|||||
|
2021
Q2 | $43.4M | Sell |
|
|||||
|
2021
Q1 | $36.3M | Buy |
|
|||||
|
2020
Q4 | $31.5M | Sell |
|
|||||
|
2020
Q3 | $38M | Buy |
|
|||||
|
2020
Q2 | $38.7M | Buy |
|
|||||
|
2013
Q4 | – | Sell |
|
|||||
|
2013
Q3 | $6.18M | Buy |
|